NASDAQ:PODD - Insulet Stock Price, Forecast & News

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet Co. (NASDAQ:PODD) issued its earnings results on Tuesday, November, 5th. The medical instruments supplier reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by $0.02. The medical instruments supplier had revenue of $192.12 million for the quarter, compared to analysts' expectations of $179.50 million. The business's revenue was up 27.2% on a year-over-year basis. During the same quarter last year, the company earned $0.03 EPS. View Insulet's Earnings History.

Insulet is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Insulet.

Insulet will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

17 brokerages have issued twelve-month price targets for Insulet's shares. Their forecasts range from $100.00 to $213.00. On average, they anticipate Insulet's share price to reach $162.06 in the next twelve months. This suggests that the stock has a possible downside of 23.7%. View Analyst Price Targets for Insulet.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 8 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Insulet.

News coverage about PODD stock has trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Insulet earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned headlines about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Insulet.

Some companies that are related to Insulet include Abbott Laboratories (ABT), ABIOMED (ABMD), CONMED (CNMD), ProShares UltraShort DJ-UBS Commodity (CMD), Synthorx (THOR), AtriCure (ATRC), AngioDynamics (ANGO), Alphatec (ATEC), Accuray (ARAY), Fc Global Realty (FCRE), Navidea Biopharmaceuticals (NAVB), Baxter International (BAX), Becton Dickinson and (BDX), Boston Scientific (BSX) and Cardiovascular Systems (CSII).

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include Alibaba Group (BABA), Netflix (NFLX), NVIDIA (NVDA), DexCom (DXCM), Splunk (SPLK), Tandem Diabetes Care (TNDM), Adobe (ADBE), Roku (ROKU), salesforce.com (CRM) and Veeva Systems (VEEV).

Insulet's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include William Blair Investment Management LLC (2.59%), Fred Alger Management LLC (2.34%), Eagle Asset Management Inc. (0.99%), Lord Abbett & CO. LLC (0.88%), Renaissance Technologies LLC (0.81%) and Bank of New York Mellon Corp (0.80%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Institutional Ownership Trends for Insulet.

PODD stock was sold by a variety of institutional investors in the last quarter, including CSS LLC IL, Fred Alger Management LLC, Goldman Sachs Group Inc., Jennison Associates LLC, Eagle Asset Management Inc., Russell Investments Group Ltd., Marshall Wace North America L.P. and First Trust Advisors LP. Company insiders that have sold Insulet company stock in the last year include Aiman Abdel-Malek, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Insider Buying and Selling for Insulet.

PODD stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Beacon Investment Advisory Services Inc., Sumitomo Mitsui Trust Holdings Inc., UBS Asset Management Americas Inc., Swiss National Bank, SG Americas Securities LLC, Cubist Systematic Strategies LLC and Trexquant Investment LP. View Insider Buying and Selling for Insulet.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PODD stock can currently be purchased for approximately $212.32.